Recent spatial gene expression technologies enable comprehensive measurement of
transcriptomic profiles while retaining spatial context. However, existing analysis methods …

Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …

Many potential targets for CAR-T cells in solid tumors are expressed in some normal tissues,
raising concern for off-tumor toxicity. Following lymphodepletion, CAR-T cells targeting the …

Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective
treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically …

Purpose: Pancreatic ductal adenocarcinoma (PDA) is rarely cured, and single-agent
immune checkpoint inhibition has not demonstrated clinical benefit despite the presence of …

Immunotherapy fails to cure most cancer patients. Preclinical studies indicate that
radiotherapy synergizes with immunotherapy, promoting radiation-induced antitumor …

Background Though currently approved immunotherapies, including chimeric antigen
receptor T cells and checkpoint blockade antibodies, have been successfully used to treat …

Purpose: Leiomyosarcoma and liposarcoma frequently express PD-L1 but are generally
resistant to PD-1/PD-L1 inhibition (immune checkpoint inhibitor). Trabectedin is FDA …

Purpose: To characterize changes in the soft-tissue sarcoma (STS) tumor immune
microenvironment induced by standard neoadjuvant therapy with the goal of informing …

Background Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue
sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the …